Product
Lenvatinib + Tislelizumab + CapeOX chemotherapy
1 clinical trial
1 indication
Indication
Stomach CancerClinical trial
Tislelizumab Plus CapeOX ± Lenvatinib as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore: A Multi-center, Prospective, Phase II StudyStatus: Recruiting, Estimated PCD: 2026-08-01